VRHID (Veri Medtech Holdings) Liabilities-to-Assets : 0.78 (As of Dec. 2021)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

VRHID Veri Medtech Holdings Inc VRHID
35 GF Score
Price $6.00
View Full Analysis

What is Veri Medtech Holdings Liabilities-to-Assets?

Veri Medtech Holdings VRHID +2.28% 35 Liabilities-to-Assets is 0.78 as of Dec. 2021. GuruFocus rates VRHID with a GF Score™ of 35/100.

Liabilities-to-Assets is a solvency ratio indicating how much of the company’s assets are made of liabilities, calculated as total liabilities divided by total asset. Veri Medtech Holdings's Total Liabilities for the quarter that ended in Dec. 2021 was $0.27 Mil. Veri Medtech Holdings's Total Assets for the quarter that ended in Dec. 2021 was $0.35 Mil. Therefore, Veri Medtech Holdings's Liabilities-to-Assets Ratio for the quarter that ended in Dec. 2021 was 0.78.


Veri Medtech Holdings  (OTCPK:VRHID) Liabilities-to-Assets Explanation

Liabilities-to-Assets is a solvency ratio indicating how much of the company’s assets are made of liabilities. It can vary greatly across different industries, as they have different capital structure. A high Liabilities-to-Assets ratio (more leveraged) suggests that the company might have potential solvency problems, or even a signal of financial distress. Conversely, a low Liabilities-to-Assets ratio usually indicates a healthy financial situation. However, it may also suggest that the company is not expanding or not making good use of debt.


Veri Medtech Holdings Liabilities-to-Assets Related Terms


Veri Medtech Holdings Liabilities-to-Assets Historical Data

* Premium members only.

The historical data trend for Veri Medtech Holdings's Liabilities-to-Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Veri Medtech Holdings Liabilities-to-Assets Chart

Veri Medtech Holdings Annual Data
Trend Dec21
Liabilities-to-Assets
0.78

Veri Medtech Holdings Semi-Annual Data
Dec21
Liabilities-to-Assets 0.78

VRHID vs MMVVF, BLMZ, MVNC: Liabilities-to-Assets Comparison

For the Health Information Services subindustry, Veri Medtech Holdings's Liabilities-to-Assets, along with its competitors' market caps and Liabilities-to-Assets data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Veri Medtech Holdings Liabilities-to-Assets vs Healthcare Providers & Services Industry

For the Healthcare Providers & Services industry and Healthcare sector, Veri Medtech Holdings's Liabilities-to-Assets distribution charts can be found below:

* The bar in red indicates where Veri Medtech Holdings's Liabilities-to-Assets falls into.


VRHID
35GF Score
Veri Medtech Holdings Inc VRHID
Liabilities-to-Assets is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Veri Medtech Holdings Liabilities-to-Assets Calculation

Liabilities-to-Assets ratio measures the portion of the total liabilities to the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.

Liabilities-to-Assets ratio is calculated by dividing total liabilities by total asset.

Veri Medtech Holdings's Liabilities-to-Assets Ratio for the fiscal year that ended in Dec. 2021 is calculated as:

Liabilities-to-Assets (A: Dec. 2021 )=Total Liabilities/Total Assets
=0.272/0.35
=0.78

Veri Medtech Holdings's Liabilities-to-Assets Ratio for the quarter that ended in Dec. 2021 is calculated as

Liabilities-to-Assets (Q: Dec. 2021 )=Total Liabilities/Total Assets
=0.272/0.35
=0.78

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Liabilities-to-Assets →
What does a Liabilities-to-Assets of 0.78 mean?
Veri Medtech Holdings (VRHID) has a Liabilities-to-Assets of 0.78 as of Dec. 2021. Liabilities-to-Assets equals total liabilities divided by total assets. It measures financial leverage. View historical data on Veri Medtech Holdings and its competitors.
Is Veri Medtech Holdings' Liabilities-to-Assets too high?
Veri Medtech Holdings' current Liabilities-to-Assets is 0.78. Overall, Veri Medtech Holdings has a GF Score™ of 35/100, reflecting its overall financial health beyond just this single metric.
How does Veri Medtech Holdings' Liabilities-to-Assets compare to MMVVF and BLMZ?
Veri Medtech Holdings' Liabilities-to-Assets of 0.78 can be compared against companies in the Healthcare Providers & Services industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Liabilities-to-Assets for a Healthcare Providers & Services company?
A good Liabilities-to-Assets depends on the Healthcare Providers & Services industry context. However, Liabilities-to-Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Liabilities-to-Assets mean?
A high Liabilities-to-Assets can signal that a stock is expensive relative to its fundamentals. Liabilities-to-Assets equals total liabilities divided by total assets. It measures financial leverage. View historical data on Veri Medtech Holdings and its competitors. Veri Medtech Holdings's current Liabilities-to-Assets is 0.78. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Veri Medtech Holdings stock overvalued right now?
Veri Medtech Holdings (VRHID) has a current Liabilities-to-Assets of 0.78. The current Liabilities-to-Assets is 0.78. Veri Medtech Holdings' overall GF Score™ is 35/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Liabilities-to-Assets calculated?
Liabilities-to-Assets is calculated from a company's financial statements. For Veri Medtech Holdings (VRHID), the current Liabilities-to-Assets is 0.78 as of Dec. 2021. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Veri Medtech Holdings Business Description

Address 1660 International Drive, Suite 600, McClean, VA, USA, 22101
Veri Medtech Holdings Inc is a healthcare technology company that offers alternative medicine, personalized diagnostics, and wellness medication on demand. The company leverages telehealth infrastructure, diagnostic intelligence, and scalable digital systems to meet the growing demand for accessible, stigma-free healthcare. Strategically positioned for growth, Veri MedTech actively explores acquisitions that complement its core capabilities and enhance patient engagement across emerging sectors of alternative medicine, longevity, and wellness science. With an integration and operational efficiency track record, the company drives accelerated revenue through the continuous generation of high-value patient databases and recurring service models.
35GF Score

Get the complete analysis for VRHID

Liabilities-to-Assets is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$6.00
Price